Source: Breathe, 17 (4) 210112; 10.1183/20734735.0112-2021



Rating:

Share or cite this content

Citations should be made in the following way:
Daniel H. Tewkesbury, Rebecca C. Robey, Peter J. Barry. Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy. Breathe, 17 (4) 210112; 10.1183/20734735.0112-2021

Member's Comments

No comment yet.

Related content which might interest you: ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies Source: Eur Respir J, 56 (6) 2000946; 10.1183/13993003.00946-2020 Year: 2020 Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis Source: Eur Respir J, 51 (6) 1702457; 10.1183/13993003.02457-2017 Year: 2018 Genomically-guided therapies: a new era for cystic fibrosis Source: Virtual Congress 2020 – European Reference Network for rare lung diseases (ERN-LUNG): acting for improved cross-border management of rare diseases Year: 2020 Personalised medicine for cystic fibrosis: treating the basic defect Source: Eur Respir Rev 2013; 22: 3-5 Year: 2013 Update on new treatments for cystic fibrosis Source: Virtual Congress 2020 – Updates in cystic fibrosis Year: 2020 Cystic fibrosis: prospects for therapy of some class 1 mutations Source: Annual Congress 2007 - Cystic fibrosis: will the new biology deliver? Year: 2007 Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis Source: Eur Respir Rev 2013; 22: 58-65 Year: 2013 A European regulatory perspective on cystic fibrosis: current treatments, trends in drug development and translational challenges for CFTR modulators Source: Eur Respir Rev, 27 (148) 170124; 10.1183/16000617.0124-2017 Year: 2018 Time to breathe: Progress in precision medicine in cystic fibrosis Source: Short video discussion 2022 Year: 2022 The impact of personalised therapies on respiratory medicine Source: Eur Respir Rev 2013; 22: 72-74 Year: 2013 CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways Source: Eur Respir Rev, 29 (156) 190068; 10.1183/16000617.0068-2019 Year: 2020 Targeting CFTR as a therapy for cystic fibrosis Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung Year: 2010 Revisiting α1-antitrypsin therapy in cystic fibrosis: can it still offer promise? Source: Eur Respir J 2007; 29: 229-230 Year: 2007 Late Breaking Abstract: Denufosol: A novel ion channel regulator and investigational early-intervention therapy for cystic fibrosis Source: Annual Congress 2010 - Cystic fibrosis: lung disease and much more Year: 2010 Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease Source: Eur Respir Rev, 29 (155) 190112; 10.1183/16000617.0112-2019 Year: 2020 Health-economic aspects of cystic fibrosis screening and therapy Source: Eur Respir Monogr 2014; 64: 304-319 Year: 2014 Pharmacology and regulation of ENaC function: implication in cystic fibrosis Source: Annual Congress 2009 - Novel regulators of alveolar liquid clearance Year: 2009 The cystic fibrosis transmembrane conductance regulator and its modulators: clinical implications Source: Virtual Congress 2020 – Respiratory infections Year: 2020 Advanced cell culture techniques and personalised medicine for cystic fibrosis Source: International Congress 2015 – Respiratory research in the Netherlands Year: 2015 Gene therapy for cystic fibrosis: successes and challenges Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=79 Year: 2006